A Chip on the Shoulder of Brain Surgery

Science Corp isn't diving into brain surgery just for the thrill. The company plans to place a tiny sensor on a human brain during an already scheduled operation. The 520-electrode chip, no bigger than a pea, will rest on the brain's surface, recording activity without digging deep. This isn't a science fiction experiment—it's a calculated move to test the sensor's safety and effectiveness. The first trial could happen in 2027, led by Murat Günel, chair of neurosurgery at Yale. Instead of recruiting healthy volunteers, Science Corp is targeting patients who need brain surgery anyway, like stroke victims. This "opportunistic" approach cuts down on extra risk for patients already facing major procedures. What makes Science Corp's tech different isn't just the sensor—it's what might come next. The company is betting big on a future where lab-grown neurons, modified to react to light, could bridge the gap between electronics and the brain. Imagine a chip that doesn't just record signals but grows with the brain itself, forming a natural connection. For now, though, the first sensor won't include these biohybrid components. It's just a test to see if the hardware can safely capture brain activity without issues. If it works, the real challenge begins: integrating living neurons into the mix.Science Corp isn't alone in the brain-computer interface race. Neuralink, founded by ex-employees of this very company, has already implanted its device in over 20 people. Paradromics is pushing for faster data transfer, while Synchron is taking a less invasive route by inserting its device through blood vessels. Each company is placing different bets. Neuralink is focused on dense electrodes and automation. Paradromics wants raw speed. Synchron prioritizes ease of surgery over signal quality. Science Corp? It's betting that biology—specifically, lab-grown neurons—will win the long game. On another front, Science Corp is already making waves with its retinal implant, PRIMA. The device, smaller than a grain of salt, sits under the retina and restores vision in patients with severe eye damage. Results from a 12-month trial showed significant improvement in 38 patients, with most able to read letters and words. The implant, powered by specialized glasses, is already approved in some regions and could hit European markets by mid-2026. It's a rare bright spot in a field where most treatments only slow vision loss, not restore it. The company's latest funding round, a $230 million boost in 2026, values Science Corp at $1. 5 billion. With 150 employees, it's growing fast but still a small player in a crowded field. The real test will be whether its biohybrid vision—neurons and all—can outperform the competition. For now, the first sensor placement is just the beginning. It's a gamble on a future where brains and machines might one day work as one.